Sign In
Buy MBIO
$0.741
-0.0201 (-2.64%)
At Close: Jun 03, 2026
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?
09:21am, Monday, 17'th Jun 2024
Penny stock Mustang Bio Inc MBIO shares are trading higher on a strong session volume of 90 million versus an average volume of 3.17 million, as per data from Benzinga Pro.
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months
Why Is Mustang Bio (MBIO) Stock Up 58% Today?
08:04am, Wednesday, 22'nd May 2024
Mustang Bio (NASDAQ: MBIO ) stock is taking off on Wednesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 13.9 million shares of MBI
HC Wainwright Analysts Lower Earnings Estimates for Mustang Bio, Inc. (NASDAQ:MBIO)
01:38am, Monday, 20'th May 2024
Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) – Analysts at HC Wainwright reduced their Q2 2024 earnings estimates for Mustang Bio in a research note issued to investors on Thursday, May 1
Mustang Bio Announces Closing of $4 Million Public Offering
04:01pm, Thursday, 02'nd May 2024
Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 Million Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 Million
Mustang Bio Announces Pricing of $4 Million Public Offering
08:00pm, Monday, 29'th Apr 2024
WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's me
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
09:00am, Thursday, 28'th Mar 2024
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
04:05pm, Monday, 11'th Mar 2024
WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's me
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
08:30am, Thursday, 11'th Jan 2024
WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's med
Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
04:05pm, Tuesday, 14'th Nov 2023
WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in
Updated interim data from Mustang's multicenter Phase 1/2 clinical trial demonstrate favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients Updated interim data from
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
02:15pm, Monday, 30'th Oct 2023
WORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's med
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12:30pm, Thursday, 26'th Oct 2023
WORCESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's med
